Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib + TIL + IL-2 in Metastatic Melanoma
NCT01659151Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Aug 2012
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous tumor-infiltrating lymphocytes in melanoma, sponsored by Moffitt Cancer Center. Started Aug 2012; status: completed.
02
Drugs
autologous tumor-infiltrating lymphocytes
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01659151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01659151.